RxDoctor Payments DataLook up a doctor →

Joshua Liu

Rheumatology · Morristown, NJNPI 1255785168

Payments from drug & device makers

$8,594in general payments, 2019–2025

Across 487 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • Johnson & Johnson$1K
  • Novartis$880
  • UCB, Inc.$561
  • Mallinckrodt Hospital Products Inc.$473
  • plus $3K from 24 others

What the payments were for

  • Travel & lodging$2363%
  • Food & beverage$7,73990%
  • Education$6197%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,594 in reported general payments places this provider in the 75th percentile of 234 rheumatology providers in New Jersey.

See all rheumatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$297,781
Medicare patients
213
Services billed
18,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib34$250,700
Orencia ClickjectAbatacept27$151,630
Humira(Cf) PenAdalimumab20$135,405
OtezlaApremilast21$107,359
Cimzia (2 Pack)Certolizumab Pegol12$70,232
Actemra ActpenTocilizumab14$65,842
Colchicine25$3,362
Mycophenolate Mofetil17$3,063
Hydroxychloroquine Sulfate58$2,005
MethotrexateMethotrexate Sodium75$1,915
Diclofenac Sodium22$1,052
Prednisone97$908
Gabapentin51$582
Sulfasalazine DrSulfasalazine18$529
Alendronate Sodium58$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,444$250,70034 claims
AmgenOtezla$1,409$107,35921 claims
UCB, Inc.Cimzia (2 Pack)$561$70,23212 claims
Scilex Pharmaceuticals Inc.Colchicine$153$3,36225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 234 rheumatology providers in New Jersey.

Other rheumatology in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →